Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: A sub-analysis of the iCOR randomized trial.


Journal

Journal of telemedicine and telecare
ISSN: 1758-1109
Titre abrégé: J Telemed Telecare
Pays: England
ID NLM: 9506702

Informations de publication

Date de publication:
Historique:
pubmed: 9 9 2018
medline: 18 11 2020
entrez: 9 9 2018
Statut: ppublish

Résumé

The efficacy of telemedicine in the management of patients with chronic heart failure and left ventricular ejection fraction ≥40% is poorly understood. The aim of our analysis was to evaluate the efficacy of a telemedicine-based intervention specifically in these patients, as compared to standard of care alone. The Insuficiència Cardiaca Optimització Remota (iCOR) study was a single centre, randomised, controlled trial, designed to evaluate a telemedicine intervention added to an existing hospital/primary care multidisciplinary, integrated programme for chronic heart failure patients. 178 participants were randomised to telemedicine or usual care, and were followed for six months. For the present sub-analysis, only iCOR participants (n = 116) with left ventricular ejection fraction ≥40% were included. The primary study endpoint was the incidence of an acute non-fatal heart failure event, defined as a new episode of worsening of symptoms and signs consistent with acute heart failure requiring intravenous diuretic therapy. The healthcare-related costs in each study group were also evaluated. The incidence of the first occurrence of the primary endpoint was significantly lower in the telemedicine arm (22% vs 56%, p<0.001), with a hazard ratio of 0.33 comparing to the usual care arm (95% confidence interval 0.17–0.64). Telemedicine was also associated with lower mean overall chronic heart failure care-related costs compared to usual care (8163€ vs 4993€, p=0.001). The results were consistent in both left ventricular ejection fraction of 40–49% and left ventricular ejection fraction ≥50% patients. Our results suggest that telemedicine is a promising strategy for the management of chronic heart failure patients with left ventricular ejection fraction ≥40%. These findings should be replicated in larger cohorts.

Sections du résumé

Background
The efficacy of telemedicine in the management of patients with chronic heart failure and left ventricular ejection fraction ≥40% is poorly understood. The aim of our analysis was to evaluate the efficacy of a telemedicine-based intervention specifically in these patients, as compared to standard of care alone.
Methods
The Insuficiència Cardiaca Optimització Remota (iCOR) study was a single centre, randomised, controlled trial, designed to evaluate a telemedicine intervention added to an existing hospital/primary care multidisciplinary, integrated programme for chronic heart failure patients. 178 participants were randomised to telemedicine or usual care, and were followed for six months. For the present sub-analysis, only iCOR participants (n = 116) with left ventricular ejection fraction ≥40% were included. The primary study endpoint was the incidence of an acute non-fatal heart failure event, defined as a new episode of worsening of symptoms and signs consistent with acute heart failure requiring intravenous diuretic therapy. The healthcare-related costs in each study group were also evaluated.
Results
The incidence of the first occurrence of the primary endpoint was significantly lower in the telemedicine arm (22% vs 56%, p<0.001), with a hazard ratio of 0.33 comparing to the usual care arm (95% confidence interval 0.17–0.64). Telemedicine was also associated with lower mean overall chronic heart failure care-related costs compared to usual care (8163€ vs 4993€, p=0.001). The results were consistent in both left ventricular ejection fraction of 40–49% and left ventricular ejection fraction ≥50% patients.
Conclusions
Our results suggest that telemedicine is a promising strategy for the management of chronic heart failure patients with left ventricular ejection fraction ≥40%. These findings should be replicated in larger cohorts.

Identifiants

pubmed: 30193564
doi: 10.1177/1357633X18796439
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

64-72

Auteurs

Santiago Jiménez-Marrero (S)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

Sergi Yun (S)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Department of Internal Medicine, Bellvitge University Hospital, Spain.

Miguel Cainzos-Achirica (M)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins Medical Institutions, USA.

Cristina Enjuanes (C)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

Alberto Garay (A)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

Nuria Farre (N)

Heart Failure Unit, Hospital del Mar, Spain.
Heart Diseases Biomedical Research Group (GREC), Hospital del Mar Biomedical Research Institute (IMIM), Spain.
Department of Medicine, Universitat Autònoma de Barcelona, Spain.

Jose M Verdú (JM)

Department of Medicine, Universitat Autònoma de Barcelona, Spain.
Sant Martí de Provençals Primary Care Center, Institut Catalá de la Salut, Spain.
Primary Care Research Institute Jordi Gol (IDIAP), Spain.

Anna Linas (A)

Heart Failure Unit, Hospital del Mar, Spain.
Heart Diseases Biomedical Research Group (GREC), Hospital del Mar Biomedical Research Institute (IMIM), Spain.

Pilar Ruiz (P)

Heart Failure Unit, Hospital del Mar, Spain.
Heart Diseases Biomedical Research Group (GREC), Hospital del Mar Biomedical Research Institute (IMIM), Spain.

Encarnación Hidalgo (E)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.

Esther Calero (E)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Primary Care Research Institute Jordi Gol (IDIAP), Spain.

Josep Comín-Colet (J)

Community Heart Failure Program, Bellvitge University Hospital, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Department of Clinical Sciences, University of Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH